Larvol Veri

BIOMARKER:

CBL mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

CBL mutation CBL mutation	Acute Myelogenous Leukemia AML	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
CBL mutation CBL mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine/daunorubicin liposomal formulation Resistant : C3
CBL mutation CBL mutation	Sarcoma Sarcoma	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3
CBL mutation CBL mutation	Non Small Cell Lung Cancer NSCLC	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3
CBL mutation CBL mutation	Melanoma Melanoma	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3
CBL mutation CBL mutation	Non Small Cell Lung Cancer NSCLC	SU11274 Sensitive: D – Preclinical SU11274 Sensitive : D
CBL mutation CBL mutation	Chronic Myelomonocytic Leukemia CMML	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D